Feb 11 2010
Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a developer of
revolutionary diagnostic systems and technology for malaria, HIV/AIDS,
hepatitis, tuberculosis and detection, announced today the
implementation of a program to accelerate the availability of the
world's first Integrated Optical BioSensor (IOBS) platform. The Company
is currently reviewing research and manufacturing partnerships to
develop simple to replicate bench top versions of the IOBS platform on
which single pathogen or multiple pathogen testing assay cartridges can
be developed. This strategy is expected to significantly accelerate the
availability of this life and cost saving technology.
“It is important for us to accelerate assay test cartridge development
as we are currently scheduling our malaria clinical trial with one of
the most prestigious malaria research institutions in India with
additional trials being organized in Kenya and Mexico”
The Company’s initial strategy was to fully produce the handheld version
of the IOBS platform and to then use that platform to develop all of the
many different types of pathogen testing assay cartridges. By taking a
slightly different direction and developing desktop versions of the IOBS
platform, which can be produced more quickly, the Company will be able
to develop the single test assay cartridges for malaria, cholera, human
tuberculosis, bovine tuberculosis and HIV/AIDS in parallel to the
production of the handheld units. This approach will significantly
reduce time-to-market and make this important technology available to
the world much sooner and will allow the corporation to accelerate its
revenue growth rate.
“It is important for us to accelerate assay test cartridge development
as we are currently scheduling our malaria clinical trial with one of
the most prestigious malaria research institutions in India with
additional trials being organized in Kenya and Mexico,” commented
Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. “We are very
anxious to begin demonstrating this technology in real world settings as
we believe we will be able to lower the cost of malaria, tuberculosis,
cholera and HIV/AIDS testing to unprecedented levels while at the same
time reducing the time it takes to receive results from days or hours to
a matter of a few minutes. While we believe the production of this
device will yield significant returns for our shareholders, and this is
clearly an important priority, we have never lost sight of the fact that
there are tens of thousands of lives we may be able to save through our
important endeavors in this area.”
Source:
Biomagnetics Diagnostics Corp.